Astellas Pharma Overview

  • Year Founded
  • 1923

Year Founded

  • Status
  • Public

  • Employees
  • 14,484

Employees

  • Stock Symbol
  • 4503

Stock Symbol

  • Investments
  • 39

  • Share Price
  • $9.58
  • (As of Monday Closing)

Astellas Pharma General Information

Description

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Contact Information

Formerly Known As
Yamanouchi Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
TKS
Corporate Office
  • 2-5-1, Nihonbashi-Honcho
  • Chuo-ku
  • Tokyo, 103-8411
  • Japan
+81 00-0000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Astellas Pharma Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.58 $9.56 $9.25 - $16.25 $17.2B 1.79B 7.91M $0.07

Astellas Pharma Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022
EV 23,623,976 23,623,976 25,100,359 28,035,433
Revenue 11,098,857 11,098,857 11,217,304 11,537,524
EBITDA 1,269,010 1,269,010 1,763,664 2,095,097
Net Income 117,967 117,967 729,153 1,104,526
Total Assets 23,585,088 23,585,088 18,435,922 19,110,478
Total Debt 6,078,732 6,078,732 2,401,981 2,301,144
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Astellas Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Astellas Pharma‘s full profile, request access.

Request a free trial

Astellas Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, dev
Pharmaceuticals
Tokyo, Japan
14,484 As of 2023
00000000

000000

t ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerci
0000000000000
Bengaluru, India
00000 As of 0000
000.00
00000 0000-00-00
00000000 000.00

00000

eniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo c
000000000000000
Ahmedabad, India
00000 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Astellas Pharma Competitors (44)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biocon Formerly PE-Backed Bengaluru, India 00000 000.00 00000000 000.00
Intas Pharmaceuticals Private Equity-Backed Ahmedabad, India 00000 000.00 00000000000 000.00
Novartis Corporation Basel, Switzerland 00000 0000 000000000 0000
EPIRUS Biopharmaceuticals Corporation Boston, MA 00 000.00 000000000000 000.00
Coherus Biosciences Formerly VC-backed Redwood City, CA 000 00000 000000000 00 00000
You’re viewing 5 of 44 competitors. Get the full list »

Astellas Pharma Patents

Astellas Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024020942-A Packaging boxes, packaging box assembly sheets, and packaging methods for packaging boxes Pending 02-Aug-2022
JP-7440710-B1 Heterocyclic compound that acts on g12d mutant kras protein Active 21-Jul-2022 0
AU-2022206771-A1 Drug conjugates comprising antibodies against claudin 18.2 Pending 21-Jul-2022 00000000000
JP-2024056893-A Heterocyclic compounds acting on g12d mutant kras protein Pending 21-Jul-2022
JP-2024002723-A Pocket forming device and blister packaging machine Pending 24-Jun-2022
To view Astellas Pharma’s complete patent history, request access »

Astellas Pharma Executive Team (43)

Name Title Board Seat Contact Info
Masao Yoshida President & Chief Executive Officer Americas Operations
Naoki Okamura Representative Director, President & Chief Executive Officer
Hideki Shima Chief Manufacturing Officer & President of Pharmaceutical Technology
Mark Reisenauer President, US
Atsushi Kitamura Chief Financial Officer
You’re viewing 5 of 43 executive team members. Get the full list »

Astellas Pharma Board Members (10)

Name Representing Role Since
00000 0000000 Self Director 000 0000
0000000000 000000 Astellas Pharma Board Member & Vice President 000 0000
00000 00000000 00. Astellas Pharma Representative Director & Chairman of the Board 000 0000
00000 0000000 Astellas Pharma Representative Director, President & Chief Executive Officer 000 0000
00000 000000000 Astellas Pharma Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Astellas Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Astellas Pharma Investments & Acquisitions (39)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Joint Venture (Astellas / Sumitomo Mitsui / Takeda) 22-Apr-2024 00000 0000 Drug Discovery 00000 000
Propella Therapeutics 21-Dec-2023 0000000000 00000 Biotechnology 00000 000
Poseida Therapeutics 07-Aug-2023 0000 0000 Drug Discovery
IVERIC bio 11-Jul-2023 0000000000 00.00 Biotechnology 000000000
Cha Biotech (Eye-Cell Therapies Technology) 02-Mar-2023 Corporate Asset Purchase 0000 Buildings and Property
You’re viewing 5 of 39 investments and acquisitions. Get the full list »

Astellas Pharma Subsidiaries (11)

Company Name Industry Location Founded
Xyphos Biosciences Biotechnology South San Francisco, CA 2017
Potenza Therapeutics Biotechnology Cambridge, MA 0000
Universal Cells Biotechnology Seattle, WA 0000
Nanna Therapeutics Drug Discovery Cambridge, United Kingdom 0000
Mitobridge Drug Discovery Cambridge, MA 0000
You’re viewing 5 of 11 subsidiaries. Get the full list »

Astellas Pharma ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

18.3 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

0.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

0.00

Percentile

To view Astellas Pharma’s complete esg history, request access »

Astellas Pharma Exits (6)

Company Name Exit Date Exit Type Exit Size Status Buyers
Kanyos Bio 02-Jun-2015 00000 00000 00 000.00 Completed
  • 5 buyers
Kanyos Bio 29-May-2015 00000 0000000 00000 Completed
  • 2 buyers
Amgen Astellas BioPharma 01-Oct-2013 00000 0000000 Completed
  • 2 buyers
Qutenza (Commercialization Rights in Europe) 22-Jun-2009 000000000 00000 00 0000 Completed
  • 00000000 000000
FibroGen 10-Jan-2007 Later Stage VC 0000 Completed
  • 2 buyers
You’re viewing 5 of 6 exits. Get the full list »

Astellas Pharma FAQs

  • When was Astellas Pharma founded?

    Astellas Pharma was founded in 1923.

  • Who is the CEO of Astellas Pharma?

    Masao Yoshida and Naoki Okamura are the CEOs of Astellas Pharma.

  • Where is Astellas Pharma headquartered?

    Astellas Pharma is headquartered in Tokyo, Japan.

  • What is the size of Astellas Pharma?

    Astellas Pharma has 14,484 total employees.

  • What industry is Astellas Pharma in?

    Astellas Pharma’s primary industry is Pharmaceuticals.

  • Is Astellas Pharma a private or public company?

    Astellas Pharma is a Public company.

  • What is Astellas Pharma’s stock symbol?

    The ticker symbol for Astellas Pharma is 4503.

  • What is the current stock price of Astellas Pharma?

    As of 17-Jun-2024 the stock price of Astellas Pharma is $9.58.

  • What is the current market cap of Astellas Pharma?

    The current market capitalization of Astellas Pharma is $17.2B.

  • What is Astellas Pharma’s current revenue?

    The trailing twelve month revenue for Astellas Pharma is $11.1B.

  • Who are Astellas Pharma’s competitors?

    Biocon, Intas Pharmaceuticals, Novartis, EPIRUS Biopharmaceuticals, and Coherus Biosciences are some of the 44 competitors of Astellas Pharma.

  • What is Astellas Pharma’s annual earnings per share (EPS)?

    Astellas Pharma’s EPS for 12 months was $0.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »